[1] HOFFMAN R, MINTA G S, DUSSAILLAT R G. Patterns and mechanisms of instent restenosis:a serial intravascular ultrasound study, 1996
[2] NAKAYAMA Y. Fabrication of drug-eluting covered stents with micropores and differential coating of heparin and FK506. 2003(2). doi:10.1016/S1522-1865(3)00143-4
[3] 谭丽丽, 杨柯, 张炳春. 冠脉支架表面载药涂层的制备和性能. 材料研究学报2004(4)
[4] NEW G, MOSES J W, ROUBIN G S. Estrogen-eluting,phosphorylcholinc-coated stent implantation is associated with reduced ncointimal form ation but no delay in vascular repair in aporcine coronary mode. 2002(2). doi:10.1002/ccd.10339
[5] LINCOFF A M, FURST J G, ELLIS S G. Poly-L/D-lactide stents as intravascular devices-an experimental study. 1997(4). doi:10.1016/S0735-1097(96)00584-0
[6] FRECCESCO L, LEONARDO B. Drug-eluting stent, 2003(3)
[7] 吴红波, 付国胜. 紫杉醇预防支架内再狭窄的作用. 国外医学(心血管疾病分册)2004(2). doi:10.3969/j.issn.1673-6583.2004.02.015
[8] SOLLTT S J, CHENG L, PAULY R R. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. 1995. doi:10.1172/JCI117867
[9] DRACHMAN D E, EDELMAN E R, SEIFERT P. Neointimal thickeneing after stent delivery of paclitaxel:change in composition and arrest of growth over six months. 2003(7). doi:10.1016/S0735-1097(0)01020-2
[10] HELDMAN A W, CHENG L, JENKINS G M. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis, 2001(18)
[11] GERSBLICK A H, DE S I, CHEVALIER B. Inhibition of restenosis with a paclitaxel-eluting,polymer-free coronary stent:the European evaluation of paclitaxeleluting stent(ELUTES)trial. 2004(4). doi:10.1161/01.CIR.0000109694.58299.A0
[12] GRUBE E, SILBER S, HAUPTMANN K E. TAXUS Ⅰ:six-and twelve-month results from a randomized.double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. 2003(1). doi:10.1161/01.CIR.0000047700.58683.A1
[13] TANBE K, SERRUYS P W, GRUBE E. TAXUS Ⅲ trial:instent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. 2003(4). doi:10.1161/01.CIR.0000048184.96491.8A
[14] POOM M, MARX S O, GALLO R. Rapmycin inhibits vascular smooth muscle cell migration, 1996
[15] SOUSA J E, COSTA M A, ABIZAID A. Lack of neointimal proliferation after implantation ofsiro limuscoated stents in human coronary arteries:aquantitative coronary angiography and three dimensional intravascular ultrasound study, 2001(2)
[16] SERRUYS P W, DEGERTEKIN M, TANABE K. Intravascular ultrasound findings in the multicenter,randomized,double-blind ravel(randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions)trial. 2002. doi:10.1161/01.CIR.0000025585.63486.59
[17] MOSES J W, LEON M B, POPMA J J. Sirolimus-eluting stents versus standard stents in patients with stenosis in a nativecoronary artery. 2003. doi:10.1056/NEJMoa035071
[18] 邱洪, 高润霖, 唐智荣. Mytrolimus药物洗脱支架预防支架内再狭窄的实验研究. 中华心血管病杂志2005(6)
[19] 倪中华, 易红, 王跃轩. 预防心血管再狭窄纳米颗粒载药涂层支架的研究. 东南大学学报(自然科学版)2004(6) |
